Table 1.
Patient demographics of overall patients.
| Variable | PLaCT risk group | P value | ||
|---|---|---|---|---|
| Good | Intermediate | Poor | ||
| Patients, n (%) | 105 (35) | 106 (35) | 89 (30) | |
| Median age (range), years | 65 (28–83) | 68 (25–87) | 71 (31–96) | 0.0004 |
| Sex, n (%) | ||||
| Male | 23 (22) | 66 (62) | 37 (41) | 0.0025 |
| Female | 82 (78) | 40 (38) | 52 (58) | |
| ECOG PS, n (%) | ||||
| 0 | 68 (65) | 33 (31) | 18 (20) | < 0.0001 |
| 1 | 28 (27) | 46 (43) | 30 (34) | |
| 2 | 3 (3) | 14 (13) | 12 (13) | |
| 3 | 0 (0) | 5 (5) | 18 (20) | |
| 4 | 2 (2) | 3 (3) | 8 (9) | |
| Unknown | 4 (4) | 5 (5) | 3 (3) | |
| Rescue of MUO, n (%) | ||||
| Stenting | 83 (79) | 72 (68) | 62 (70) | 0.0001 |
| Nephrostomy | 3 (3) | 22 (21) | 21 (24) | |
| No | 19 (18) | 12 (11) | 6 (7) | |
| Worst stenotic portion, n (%) | ||||
| Upper, upper-middle, and -lower | 19 (18) | 26 (25) | 27 (30) | 0.1188 |
| Middle and middle-lower | 26 (2) | 30 (28) | 27 (30) | |
| Lower | 53 (50) | 43 (41) | 29 (33) | |
| Unknown | 8 (8) | 6 (6) | 6 (7) | |
| Median stenotic length (range), cm | 2.4 (0–14) | 2.8 (0.4–15) | 3.2 (0.5–20) | 0.0045 |
| Median WBC count (range), × 103/µL | 5.7 (0.5–20.2) | 6.5 (1.5–20.3) | 6.4 (2.4–24.8) | 0.1372 |
| Median Hb (range), g/dL | 11.2 (6.6–16.0) | 10.0 (5.5–14.5) | 9.6 (5.7–14.3) | < 0.0001 |
| Median Plt count (range), × 104/µL | 23.4 (2.2–60.7) | 23.9 (2.1–65.3) | 22.1 (2.2–67.3) | 0.7678 |
| Median CRP (range)a, mg/dL | 0.9 (0.0–26.8) | 2.0 (0.0–16.5) | 3.1 (0.0–39.0) | 0.0097 |
| Median BUN (range)a, mg/dL | 15.0 (5.2–71.4) | 23.9 (3.9–192) | 36.1 (12.0–147) | < 0.0001 |
| Median eGFR (range)a, mL/min | 57.0 (6.0–146) | 34.5 (1.0–123) | 17.3 (2.5–110) | < 0.0001 |
| Median TP (range)a, g/dL | 6.7 (4.4–8.2) | 6.3 (3.0–8.2) | 6.1 (4.3–8.4) | 0.0031 |
| Median Alb (range)a, g/dL | 3.6 (1.4–5.0) | 3.3 (1.4–4.7) | 3.2 (1.0–4.5) | < 0.0001 |
| Laterality, n (%) | ||||
| Unilateral | 92 (88) | 56 (53) | 13 (15) | < 0.0001 |
| Bilateral | 13 (12) | 50 (47) | 76 (85) | |
| Median sCr (range), mg/mL | 0.84 (0.32–5.66) | 1.44 (0.42–32.4) | 2.78 (0.44–12.9) | < 0.0001 |
| Treatment for primary cancer, n (%) | ||||
| Yes | 104 (99) | 86 (81) | 21 (24) | < 0.0001 |
| CT | 69 (66) | 72 (68) | 16 (18) | |
| RT | 2 (2) | 4 (4) | 1 (1) | |
| OP | 9 (9) | 1 (1) | 1 (1) | |
| CT + RT | 8 (8) | 3 (3) | 1 (1) | |
| CT + OP | 16 (15) | 5 (5) | 1 (1) | |
| CT + RT + OP | 0 (0) | 1 (1) | 1 (1) | |
| No | 1 (1) | 20 (19) | 68 (76) | |
ECOG PS Eastern Cooperative Oncology Group Performance Status, MUO malignant ureteral obstruction, sCr serum creatinine, WBC white blood cell, Hb hemoglobin, Plt platelet, CRP c-reactive protein, BUN blood urea nitrogen, eGFR estimated glomerular filtration rate, TP total protein, Alb albumin, CT chemotherapy, RT radiotherapy, OP operation.
aThe numbers of missing data points are 23, 2, 2, 11, and 58 in CRP, BUN, eGFR, TP, and Alb, respectively.